SEFA-1024 Market

“SEFA-1024 Market Size, Forecast, and Emerging Insight − 2034” report provides comprehensive insights about SEFA-1024 for Severe Hypertriglyceridemia (SHTG) in the seven major markets. A detailed picture of the SEFA-1024 for SHTG in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the SEFA-1024 for SHTG. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the SEFA-1024 market forecast analysis for SHTG in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in SHTG.

Drug Summary

SEFA-1024 is an oral, highly lipophilic SEFA that is designed to target the gut-liver axis and concurrently improve plasma lipids and glycemic control. NorthSea Therapeutics has concluded the Phase I clinical trial of SEFA-1024 in healthy volunteers. NorthSea Therapeutics licensed the rights to its compound, icosabutate, and a library of SEFAs from Pronova BioPharma Norge AS. The company is supported by Ysios Capital, Forbion Growth, Forbion Ventures, venBio partners, Novo Seeds, Sofinnova Investments, BGV, NSV, and Hercules Capital.

Scope of the Report 

The report provides insights into:

• A comprehensive product overview including the SEFA-1024 description, mechanism of action, dosage and administration, research and development activities in Severe Hypertriglyceridemia (SHTG).
• Elaborated details on SEFA-1024 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the SEFA-1024 research and development activities in SHTG across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around SEFA-1024.
• The report contains forecasted sales of SEFA-1024 for SHTG till 2034.
• Comprehensive coverage of the late-stage emerging therapies for SHTG.
• The report also features the SWOT analysis with analyst views for SEFA-1024 in SHTG.
• Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SEFA-1024 Analytical Perspective by DelveInsight

• In-depth SEFA-1024 Market Assessment

This report provides a detailed market assessment of SEFA-1024 for Severe Hypertriglyceridemia (SHTG) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2029 to 2034.

• SEFA-1024 Clinical Assessment

The report provides the clinical trials information of SEFA-1024 for Severe Hypertriglyceridemia (SHTG) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Severe Hypertriglyceridemia (SHTG) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SEFA-1024 dominance.
• Other emerging products for SHTG are expected to give tough market competition to SEFA-1024 and launch of late-stage emerging therapies in the near future will significantly impact the market. 
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SEFA-1024 in SHTG.
• Our in-depth analysis of the forecasted sales data of SEFA-1024 from 2029 to 2034 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SEFA-1024 in SHTG. 

Key Questions

• What is the product type, route of administration and mechanism of action of SEFA-1024?
• What is the clinical trial status of the study related to SEFA-1024 in Severe Hypertriglyceridemia (SHTG) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SEFA-1024 development?
• What are the key designations that have been granted to SEFA-1024 for SHTG?
• What is the forecasted market scenario of SEFA-1024 for SHTG?
• What are the forecasted sales of SEFA-1024 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?  
• What are the other emerging products available and how are these giving competition to SEFA-1024 for SHTG?
• Which are the late-stage emerging therapies under development for the treatment of SHTG?